ArticleCrohn's & colitis 3602026
Feasibility and clinical utility of home-based fecal immunochemical testing for self-monitoring of disease activity in ulcerative colitis.
Article in Crohn's & colitis 360, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Home-based quantitative fecal calprotectin testing has been used to improve the prognosis of ulcerative colitis (UC) patients. However, its cost and the need for specific measurement devices limit accessibility. This study explored the potential of the home-based fecal immunochemical test (FIT) for self-monitoring in patients with UC. Methods: In this prospective cohort study, we recruited patients in clinical remission who were scheduled for colonoscopy between October 2020 and October 2021. We evaluated the correlation between home-based qualitative FIT results obtained using a commercially available kit and hospital-based quantitative fecal markers, endoscopic activity, and treatment intensification. We also assessed the feasibility of continued home-based FIT. Results: Among the 54 enrolled patients, 38 tested negative and 16 tested positive using the home-based FIT. The FIT-negative patients had significantly lower hospital-based FIT and fecal calprotectin levels than the FIT-positive patients ( Conclusions: Home-based FIT is a feasible, accurate, and well-accepted tool for monitoring remission in UC and is comparable to hospital-based fecal markers (UMIN000040572).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.